MediaPharma S.r.l.
A Company focused on the discovery and development of innovative drugs for the treatment of cancer and other diseases with unmet medical need.


Humanized anti-HER3 Antibody-Drug Conjugate

MediaPharma’s scientists have generated a novel anti-HER-3 Antibody-Drug Conjugate (MP-EV20-ADC). It consists of a humanized anti-HER3 monoclonal antibody (EV20) conjugated to mono methyl auristatin F (MMAF) by means of a non-cleavable linker. In HER3 expressing cancer cell lines, this HER3-ADC shows a picomolar, specific and target-dependent killing activity. In vivo, administration of a single dose of this  HER3-ADC was effective in inducing a long lasting tumor growth inhibition of  tumor cell line-based xenografts. 
HER-3 is an attractive target for an ADC, as it is expressed in various malignancies, especially when they become resistant to previous drugs, including breast cancer (wild type or resistant to Trastuzumab and T-DM1), melanoma, lung cancer, colorectal cancer, prostate cancer,.

I commenti sono chiusi.